Ram K Shrestha1, Jon C Schommer2, Michael S Taitel3, Oscar W Garza2,4, Nasima M Camp5, Osayi E Akinbosoye6,7, Patrick G Clay8, Kathy K Byrd1. 1. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA. 2. Department of Pharmaceutical Care & Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, MN. 3. Health Analytics, Research, and Reporting, Walgreen Co., Deerfield, IL. 4. Currently, School of Clinical Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA. 5. Department of Health, Research, Informatics, and Technology, ICF, Atlanta, GA. 6. Pharmacy Analytics and Global Insights, Walgreen Co., Deerfield, IL. 7. Currently, Astellas Pharma, Tokyo, Japan; and. 8. Department of Pharmacotherapy, University of North Texas Health Science Center System College of Pharmacy, Fort Worth, TX.
Abstract
BACKGROUND: The patient-centered HIV care model (PCHCM) is an evidence-informed structural intervention that integrates community-based pharmacists with primary medical providers to improve rates of HIV viral suppression. This report assesses the costs and cost-effectiveness of the PCHCM. SETTING: Patient-centered HIV care model. METHODS: Three project sites, each composed of a medical clinic and 1 or 2 community-based HIV-specialized pharmacies, were included in the analyses. PCHCM required patient data sharing between medical providers and pharmacists and collaborative therapy-related decision making. Intervention effectiveness was measured as the incremental number of patients virally suppressed (HIV RNA <200 copies/mL at the last test in a 12-month measurement period). Microcosting direct measurement methods were used to estimate intervention costs. The cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were calculated from the health care providers' perspective. Additionally, the number of HIV transmissions averted, lifetime HIV treatment cost saved, quality-adjusted life years (QALYs) saved, and cost per QALY saved were calculated from the societal perspective, using standard methods and reported values from the published literature. RESULTS: Overall, the PCHCM annual intervention cost for the 3 project sites was $226,741. The average cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were $813, $48, and $5,039, respectively. The intervention averted 2.75 HIV transmissions and saved 12.22 QALYs and nearly $1.28 million in lifetime HIV treatment costs. The intervention was cost saving overall and at each project site. CONCLUSIONS: The PCHCM can be delivered at a relatively low cost and is a cost-saving intervention to assist patients in achieving viral suppression and preventing HIV transmission.
BACKGROUND: The patient-centered HIV care model (PCHCM) is an evidence-informed structural intervention that integrates community-based pharmacists with primary medical providers to improve rates of HIV viral suppression. This report assesses the costs and cost-effectiveness of the PCHCM. SETTING: Patient-centered HIV care model. METHODS: Three project sites, each composed of a medical clinic and 1 or 2 community-based HIV-specialized pharmacies, were included in the analyses. PCHCM required patient data sharing between medical providers and pharmacists and collaborative therapy-related decision making. Intervention effectiveness was measured as the incremental number of patients virally suppressed (HIV RNA <200 copies/mL at the last test in a 12-month measurement period). Microcosting direct measurement methods were used to estimate intervention costs. The cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were calculated from the health care providers' perspective. Additionally, the number of HIV transmissions averted, lifetime HIV treatment cost saved, quality-adjusted life years (QALYs) saved, and cost per QALY saved were calculated from the societal perspective, using standard methods and reported values from the published literature. RESULTS: Overall, the PCHCM annual intervention cost for the 3 project sites was $226,741. The average cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were $813, $48, and $5,039, respectively. The intervention averted 2.75 HIV transmissions and saved 12.22 QALYs and nearly $1.28 million in lifetime HIV treatment costs. The intervention was cost saving overall and at each project site. CONCLUSIONS: The PCHCM can be delivered at a relatively low cost and is a cost-saving intervention to assist patients in achieving viral suppression and preventing HIV transmission.
Authors: Kriti M Jain; Catherine Maulsby; Meredith Brantley; Jeeyon Janet Kim; Rose Zulliger; Maura Riordan; Vignetta Charles; David R Holtgrave Journal: AIDS Care Date: 2016-03-28
Authors: Kenneth A Freedberg; Lisa R Hirschhorn; Bruce R Schackman; Lindsey L Wolf; Lindsay A Martin; Milton C Weinstein; Susan Goldin; A David Paltiel; Carol Katz; Sue J Goldie; Elena Losina Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Ram K Shrestha; Lytt Gardner; Gary Marks; Jason Craw; Faye Malitz; Thomas P Giordano; Meg Sullivan; Jeanne Keruly; Allan Rodriguez; Tracey E Wilson; Michael Mugavero Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Jan van Lunzen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; David Asboe; Pompeyo Viciana; Félix Gutiérrez; Bonaventura Clotet; Christian Pradier; Jan Gerstoft; Rainer Weber; Katarina Westling; Gilles Wandeler; Jan M Prins; Armin Rieger; Marcel Stoeckle; Tim Kümmerle; Teresa Bini; Adriana Ammassari; Richard Gilson; Ivanka Krznaric; Matti Ristola; Robert Zangerle; Pia Handberg; Antonio Antela; Sris Allan; Andrew N Phillips; Jens Lundgren Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Olaf Degen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; Dorthe Raben; Pep Coll; Andrea Antinori; Nneka Nwokolo; Armin Rieger; Jan M Prins; Anders Blaxhult; Rainer Weber; Arne Van Eeden; Norbert H Brockmeyer; Amanda Clarke; Jorge Del Romero Guerrero; Francois Raffi; Johannes R Bogner; Gilles Wandeler; Jan Gerstoft; Felix Gutiérrez; Kees Brinkman; Maria Kitchen; Lars Ostergaard; Agathe Leon; Matti Ristola; Heiko Jessen; Hans-Jürgen Stellbrink; Andrew N Phillips; Jens Lundgren Journal: Lancet Date: 2019-05-02 Impact factor: 79.321
Authors: Daniel M Camp; Shamia J Moore; Drew Wood-Palmer; Kamini Doraivelu; Nancy M Holbrook; Rosalind N Byrd; Ameeta S Kalokhe; Mohammed K Ali; Eugene W Farber; Sophia A Hussen Journal: AIDS Patient Care STDS Date: 2022-08-26 Impact factor: 5.944